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Letter to Editor
Dronedarone: A New 
Therapeutic Alternative for 
Cardiac Arrhythmias
Sir,
As a new therapeutic agent for cardiac arrhythmias, 
dronedarone (Multaq®), a drug from Sanofi-Aventis, was 
approved by the FDA on July 2, 2009.[1] It is now available 
in the market in the form of tablets having 400 mg of 
the active ingredient. For patients requiring drug therapy 
or electroshock therapy to retain their normal rhythms, 
dronedarone is a useful option. However, treatment with 
dronedarone was associated with an increased likelihood 
in deaths due to heart failure.[2] Hence, the FDA did not 
approve dronedarone without a warning for  causing deaths 
in patients with heart failure.[3] Figure 1 shows the structure, 
the International Union of Pure and Applied Chemists   
(IUPAC) name, and chemical class of dronedarone.
For getting FDA approval, the manufacturer of dronedarone 
was compelled to add a black box warning to the package 
insert. The warning is as follows: ‘WARNING: HEART 
FAILURE: MULTAQ is contraindicated in patients with 
NYHA class IV heart failure, or NYHA class II–III 
heart failure with a recent decompensation requiring 
hospitalization or referral to a specialized heart failure clinic.’ 
The pharmacokinetics of dronedarone is dictated by 
its lipophilicity. Dronedarone is less lipophilic than 
amiodarone and consequently it has a much smaller volume 
of distribution. It has an elimination t1/2 of 24 hours as 
compared to amiodarone’s half-life of a few weeks; this is 
also attributed to the lower lipophilicity of dronedarone.[4]
In the trials in atrial fibrillation (EURIS, 2007, and 
ADONIS, 2007), significantly better maintenance of the 
sinus rhythm was observed with dronedarone than with 
placebo. In the short term, lung and thyroid function 
remained unaffected.[5] Conversely, in an another study 
(ANDROMEDA, 2007), dronedarone doubled the death 
rate as compared to placebo and the trial had to be stopped 
prematurely.[2] Later, it was found that ANDROMEDA 
enrolled patients with moderate to severe congestive heart 
failure and had a relatively sicker patient population. 
The typical adverse effects observed with dronedarone 
include nausea, diarrhea, rash, and creatinine elevation.[6]
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Figure 1: Structure of dronedarone 
IUPAC name: N-(2-butyl-3-(p-(3-(dibutylamino) propoxy)benzoyl)-5-benzofuranyl) 
methanesulfonamide; Chemical class: Benzofuran derivative